Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06006923 · ClinicalTrials.gov registry record · Phase 2
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
A Phase 2 study, sponsored by Anwaar Saeed.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT06006923 is a Phase 2 study that was terminated before completion, run by Anwaar Saeed. The registered enrollment target is 1 participants.
The verdict
NCT06006923, a Phase 2 study, was terminated before completion, sponsored by Anwaar Saeed.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining preliminary efficacy and safety, followed by a randomized phase to further examine efficacy.
Interventions
- DRUG Pembrolizumab
- DRUG Regorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-06-26 |
| Est. Completion | 2025-11-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06006923
The ClinicalTrials.gov registry entry for NCT06006923 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anwaar Saeed, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06006923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06006923 about?
NCT06006923 is a clinical study titled "Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer". This is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining preliminary efficacy and safety, followed by a randomized phase to further examine efficacy.
What is the current status of trial NCT06006923?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2024-06-26. Estimated completion is 2025-11-12.
What interventions are being tested in trial NCT06006923?
The interventions under investigation include: Pembrolizumab (DRUG), Regorafenib (DRUG).
Who is sponsoring clinical trial NCT06006923?
This trial is sponsored by Anwaar Saeed, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.